Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Halcinonide + neomycin + amphotericin is a topical combination drug formulated as a cream or ointment for the treatment of cutaneous candidiasis and steroid-responsive dermatoses such as psoriasis, eczematous dermatitis, and neurodermatitis. The combination includes: - Halcinonide, a potent corticosteroid that reduces inflammation by activating natural substances in the skin to decrease swelling, redness, and itching. - Neomycin, an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. - Amphotericin (likely amphotericin B), an antifungal agent that binds to ergosterol in fungal cell membranes causing increased membrane permeability and cell death. This multi-agent formulation provides anti-inflammatory (halcinonide), antibacterial (neomycin), and antifungal (amphotericin) effects. Clinical studies have shown it is effective for treating mixed infections involving inflammation with bacterial or fungal components[2][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Halcinonide + neomycin + amphotericin.